Resource Summary Report

Generated by NIF on Sep 4, 2026

ERK 2 (D-2)

RRID:AB_627547
Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-1647, RRID:AB_627547

Antibody Information

URL: http://antibodyregistry.org/AB_627547

Proper Citation: Santa Cruz Biotechnology Cat# sc-1647, RRID:AB_627547

Target Antigen: ERK 2 (D-2)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: Immunohistochemistry; ELISA; Western Blot; Flow Cytometry; Immunocytochemistry; Immunoprecipitation; Immunofluorescence; IF, IHC

Antibody Name: ERK 2 (D-2)

Description: This monoclonal targets ERK 2 (D-2)

Target Organism: rat, mouse, human

Antibody ID: AB_627547

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-1647

Record Creation Time: 20231110T080411+0000

Record Last Update: 20260829T182222+0000

Ratings and Alerts

No rating or validation information has been found for ERK 2 (D-2).

No alerts have been found for ERK 2 (D-2).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Aussel A, et al. (2026) Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas. Nature communications, 17(1).

Chattergoon NN, et al. (2026) B-Raf is required for normal murine cardiac development and function. American journal of physiology. Regulatory, integrative and comparative physiology, 330(6), R590.

Ojea Ramos S, et al. (2026) Hippocampal ERK2 dimerization regulates inhibitory avoidance memory reconsolidation and synaptic plasticity. iScience, 29(7), 116649.

Biancur DE, et al. (2026) Iron overload suppresses LKB1 and induces IL36G anti-tumor immunity in PDAC metastasis. Science advances, 12(29), eadz8681.

Assi M, et al. (2026) Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. Cell, 189(6), 1731.

Tan T, et al. (2025) Revisiting phosphoregulation of Cdc25C during M-phase induction. iScience, 28(1), 111603.

Doro Pereira L, et al. (2025) PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma. Cancer research communications, 5(2), 339.

Dias D, et al. (2025) MITF, TFEB, and TFE3 drive distinct adaptive gene expression programs and immune infiltration in melanoma. Cell reports, 44(12), 116499.

Pivonello C, et al. (2025) miR-375 Regulation of SSTR2 Expression in Corticotroph Pituitary Cells: Somatostatin Receptor Ligands Effects. Endocrinology, 166(8).

Biber P, et al. (2025) USP9X is a mechanosensitive deubiquitinase that controls tumor cell invasiveness and drug response through YAP stabilization. Cell reports, 44(10), 116372.

Bongiovanni C, et al. (2024) BMP7 promotes cardiomyocyte regeneration in zebrafish and adult mice. Cell reports, 43(5), 114162.

Dias D, et al. (2024) Functional specialization of MITF, TFEB and TFE3 drives radically distinct adaptive gene expression programs in melanoma. bioRxiv : the preprint server for biology.

Wang X, et al. (2023) Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. Cell reports, 42(1), 111972.

Auf der Maur P, et al. (2023) N-acetylcysteine overcomes NF1 loss-driven resistance to PI3K? inhibition in breast cancer. Cell reports. Medicine, 4(4), 101002.

Xu C, et al. (2023) The Agonist of Adenosine A1 Receptor Induced Desensitization of delta Opioid receptor-mediated Raf-1/MEK/ERK Signaling by Feedback Phosphorylation of Raf-1-Ser289/296/301. Neurochemical research, 48(5), 1531.

Iyer SR, et al. (2023) Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. EMBO molecular medicine, 15(10), e17367.

Lapadula D, et al. (2023) IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression. Molecular cancer therapeutics, 22(1), 63.

Zhang J, et al. (2023) A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling. Molecular cell, 83(15), 2692.

Martinez-Turtos A, et al. (2022) IRE1? overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response. Oncoimmunology, 11(1), 2116844.

Grima-Reyes M, et al. (2022) Tumoral microenvironment prevents de novo asparagine biosynthesis in B cell lymphoma, regardless of ASNS expression. Science advances, 8(27), eabn6491.